Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

ADA: Lilly’s once-weekly diabetes drug bests Januvia and Byetta

Late-stage trials of dulaglutide show superiority over established brands

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

Sanofi CEO Viehbacher to head EFPIA

Assumes presidency at European trade body

- PMLiVE

ADA: Sanofi eyes 2014 submissions for Lantus successor

Releases first phase III data for U300 formulation of insulin glargine

- PMLiVE

ADA: Novo Nordisk steps up Lantus challenge with new Tresiba data

But still faces at least a three-year wait for US approval

- PMLiVE

ADA: Boehringer/ Lilly’s empagliflozin shows blood glucose benefits

Phase III results for diabetes candidate also indicate significant weight loss

- PMLiVE

Cost deters NICE from Sanofi’s bowel cancer drug Zaltrap

Fails to win recommendation despite patient access scheme

- PMLiVE

Setback for AZ and BMS as Onglyza flunks cardiovascular trial

Diabetes drug fails to show benefit over placebo

- PMLiVE

Sanofi and AstraZeneca form cancer research alliances with non-profits

Will work respectively with Curie Institute in France and Cancer Research UK

- PMLiVE

US charity calls for release of diabetes drug data

American Diabetes Association demands review of incretin-based medicines linked to pancreatic cancer

- PMLiVE

FDA approves Sanofi’s four-in-one flu vaccine

But wants more safety data for hepatitis B vaccine from Dynavax

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links